Search

Setting National teaching hospital for the management of respiratory diseases, Cotonou, Benin. Objective 1) To estimate the prevalence of lung function impairment (LFI) and associated factors in patients cured of pulmonary tuberculosis (PTB); and 2) to determine the link between human immunodeficiency virus (HIV) infection and LFI occurrence. Design We performed a cross-sectional study in cured patients with smear-positive TB (PTB+) treated between 2012 and 2015. We recruited two control groups of 70 HIV-infected (HIV+/TB-) and 70 HIV-negative participants without TB (HIV-/TB-). We performed spirometry in all participants to identify LFI (obstructive, restrictive or mixed) and the 6-min walk test (6-MWT) in PTB+ participants. We assessed the factors associated with LFI using logistic regression. Results Of 4711 subjects with PTB, 241 were contacted and 189 were included. The median age was 37 years; 128 (68.0%) were male. Overall, 85 cured PTB+ patients had LFI (45.0%). Extent of initial radiological lesions, time between symptom onset and treatment, and female sex were independently associated with LFI. Fifty-five (29.1%) cured PTB+ patients had an abnormal 6-MWT; those with LFI had a higher risk of poor exercise tolerance (OR 2.23; interquartile range 1.16-4.30). We did not find any association between HIV infection and LFI. Conclusion LFI is very common in cured PTB+ patients from Benin and significantly impacts exercise tolerance.

Evaluate the tolerance of highly active antiretroviral therapy (HAART) on PLWHA treated in Cotonou to improve the quality of their follow up.Retrospective study among PLWHA agedor = 15 years, treated by HAART during the period February 2002 - January 2004 and who respond to one or more consultation of follow up. Adverse effects (AE) revealed by patients or noticed by the physician are analyzed.The study on 130 PLWHA, revealed 62,3% receiving HAART with nonnucleoside reverse transcription inhibitor and 37,7% with protease inhibitor. 75,4% presented one or more AE. Those AE were severe for 4,6% (6 patients). The frequency of AE was significantly different by drugs used. The most common events were neurosensorial (64,6%), digestive (34,6%) and dermatologic (14,6%). 2/3 of PLWHA presented AE within the first fifteen days of treatment. The patients were compliant. Only one patient stopped voluntary the treatment.The frequency and the type of AE occurred predispose patients to the non observance. Their follow up must therefore include education and surveillance guided by the profile of AE identified.

The usual clinical feature of mitochondrial toxicity is proximal myopathy. We present the report case of palpebral ptosis which occurred under zidovudine therapy The symptom remission was obtained by stopping the antiretroviral therapy. This involves an important vigilance from both doctor and patient.